Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Lipika GoyalCynthia A SirardMichael SchragMichael H KageyJennifer R EadsStacey SteinAnthony B El-KhoueiryGulam A ManjiThomas A AbramsAlok A KhoranaRebecca MiksadDevalingam MahalingamAndrew X ZhuDan G DudaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
DKN-01 300 mg was well tolerated in this combination but did not appear to have additional activity beyond historically reported efficacy with gemcitabine/cisplatin alone. Exploratory pharmacokinetic and biomarker data indicate potential antiangiogenic and immunomodulatory activity of DKN-01/chemotherapy and the need for increased dose/intensity. A study with DKN-01 600 mg in combination with a PD-1 inhibitor in BTC is ongoing.